DDInter1088 DDInter899
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Loperamide {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextropropoxyphene
Loperamide {u} (Compound) resembles {v} (Compound) Clofedanol
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
Loperamide {u} (Compound) upregulates {v} (Gene) SQLE
Loperamide {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Agonists
Loperamide {u} (Compound) downregulates {v} (Gene) MRPL12
Loperamide {u} (Compound) causes {v} (Side Effect) Nausea
Loperamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Loperamide (Compound) resembles Methadyl Acetate (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene
Loperamide (Compound) resembles Clofedanol (Compound)
Loperamide (Compound) binds CYP3A4 (Gene)
Loperamide (Compound) upregulates SQLE (Gene)
Loperamide (Compound) is included by Opioid Agonists (Pharmacologic Class)
Loperamide (Compound) downregulates MRPL12 (Gene)
Loperamide (Compound) causes Nausea (Side Effect)
Loperamide may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor